Kabi Shares Thoughts On Interchangeability, High-Concentration Humira
Follows Launch Of US Idacio Biosimilar Last Month; Tocilizumab EMA Opinion
Fresenius Kabi’s management spoke about the company’s revamped reporting segments for the second quarter, alongside its latest endeavors in biosimilars.
